Research Progress on Vitiligo and Its Comorbidities
DOI:
https://doi.org/10.53469/jcmp.2024.06(12).34Keywords:
Vitiligo, Comorbidities, Research progress, ReviewAbstract
Vitiligo is a chronic acquired depigmentation skin disease, the pathogenesis of vitiligo is not clear, previously, clinicians usually regarded vitiligo as a simple skin disease, but more and more research evidence shows that vitiligo patients are more likely to have autoimmune diseases, psychological diseases and other diseases than the general population. Therefore, this article classifies vitiligo and related diseases, and elaborates its possible pathogenesis, to provide a basis for further research on vitiligo and its comorbidities.
References
Iannella G, Greco A, Didona D, et al. Vitiligo: Pathogenesis, clinical variants and treatment approaches. Autoimmun Rev. 2016 Apr;15(4):335-43.
Katz EL, Harris JE. Translational Research in Vitiligo. Front Immunol. 2021 Mar 2;12:624517
Frisoli ML, Essien K, Harris JE. Vitiligo: Mechanisms of Pathogenesis and Treatment. Annu Rev Immunol. 2020 Apr 26;38:621-648.
Ezzedine K, Lim HW, Suzuki T, et al. Vitiligo Global Issue Consensus Conference Panelists. Revised classification/nomenclature of vitiligo and related issues: the Vitiligo Global Issues Consensus Conference. Pigment Cell Melanoma Res. 2012 May;25(3):E1-13.
Migayron L, Boniface K, Seneschal J. Vitiligo, From Physiopathology to Emerging Treatments: A Review. Dermatol Ther (Heidelb). 2020 Dec;10(6):1185-1198.
Njoo MD, Westerhof W. Vitiligo. Pathogenesis and treatment. Am J Clin Dermatol. 2001;2(3):167-81.
Rodrigues M, Ezzedine K, Hamzavi I, Pandya AG, Harris JE; Vitiligo Working Group. Current and emerging treatments for vitiligo. J Am Acad Dermatol. 2017 Jul;77(1):17-29.
Schallreuter KU, Bahadoran P, Picardo M, et al. Vitiligo pathogenesis: autoimmune disease, genetic defect, excessive reactive oxygen species, calcium imbalance, or what else? Exp Dermatol. 2008 Feb;17(2):139-40; discussion 141-60.
Lommerts JE, Bekkenk MW, Luiten RM. Vitiligo induced by immune checkpoint inhibitors in melanoma patients: an expert opinion. Expert Opin Drug Saf. 2021 Aug;20(8):883-888.
Miao X, Xu R, Fan B, et al. PD-L1 reverses depigmentation in Pmel-1 vitiligo mice by increasing the abundance of Tregs in the skin. Sci Rep. 2018 Jan 25;8(1):1605.
Speeckaert R, Speeckaert M, De Schepper S, et al. Biomarkers of disease activity in vitiligo: A systematic review. Autoimmun Rev. 2017 Sep;16(9):937-945.
Dahir AM, Thomsen SF. Comorbidities in vitiligo: comprehensive review. Int J Dermatol. 2018 Oct;57(10):1157-1164.
Li D, Liang G, Calderone R, et al. Vitiligo and Hashimoto's thyroiditis: Autoimmune diseases linked by clinical presentation, biochemical commonality, and autoimmune/oxidative stress-mediated toxicity pathogenesis. Med Hypotheses. 2019 Jul;128:69-75.
Baldini E, Odorisio T, Tuccilli C, et al. Thyroid diseases and skin autoimmunity. Rev Endocr Metab Disord. 2018 Dec;19(4):311-323.
Schunter JA, Löffler D, Wiesner T, et al. A novel FoxD3 Variant Is Associated With Vitiligo and Elevated Thyroid Auto-Antibodies. J Clin Endocrinol Metab. 2015 Oct;100(10):E1335-42.
Chivu AM, Bălășescu E, Pandia LD, Nedelcu RI, Brînzea A, Turcu G, Antohe M, Ion DA. Vitiligo-Thyroid Disease Association: When, in Whom, and Why Should It Be Suspected? A Systematic Review. J Pers Med. 2022 Dec 12;12(12):2048.
Yuan J, Sun C, Jiang S, et al. The Prevalence of Thyroid Disorders in Patients With Vitiligo: A Systematic Review and Meta-Analysis. Front Endocrinol (Lausanne). 2019 Jan 15;9:803.
Ingordo V, Cazzaniga S, Raone B, et al. Circulating autoantibodies and autoimmune comorbidities in vitiligo patients: a multicenter Italian study. Dermatology. 2014;228(3):240-249.
Fan KC, Yang TH, Huang YC. Vitiligo and thyroid disease: a systematic review and meta-analysis. Eur J Dermatol. 2018 Dec 1;28(6):750-763.
Colucci R, Lotti F, Dragoni F, et al. High prevalence of circulating autoantibodies against thyroid hormones in vitiligo and correlation with clinical and historical parameters of patients. Br J Dermatol. 2014 Oct;171(4):786-98.
Shi J, Huan X, Zhou L, et al. Comorbid Autoimmune Diseases in Patients With Myasthenia Gravis: A Retrospective Cross-Sectional Study of a Chinese Cohort. Front Neurol. 2021 Nov 22;12:790941.
Harris JE. Vitiligo and alopecia areata: apples and oranges? Exp Dermatol. 2013 Dec;22(12):785-9.
Tomaszewska K, Kozłowska M, Kaszuba A, et al. Increased Serum Levels of IFN-γ, IL-1β, and IL-6 in Patients with Alopecia Areata and Nonsegmental Vitiligo. Oxid Med Cell Longev. 2020 Aug 3;2020:5693572.
Barbulescu CC, Goldstein NB, Roop DR, et al. Harnessing the Power of Regenerative Therapy for Vitiligo and Alopecia Areata. J Invest Dermatol. 2020 Jan;140(1):29-37.
Moya EC, Bruinsma RL, Kelly KA, et al. How suitable are JAK inhibitors in treating the inflammatory component in patients with alopecia areata and vitiligo? Expert Rev Clin Immunol. 2022 Mar;18(3):189-191.
Donath MY, Hess C, Palmer E. What is the role of autoimmunity in type 1 diabetes? A clinical perspective. Diabetologia. 2014 Apr;57(4):653-5.
Malhotra N, Dytoc M. The pathogenesis of vitiligo. J Cutan Med Surg. 2013 May-Jun;17(3):153-72. doi: 10.2310/7750.2012.12005. PMID: 23673299.
Boitard C. Pancreatic islet autoimmunity. Presse Med. 2012 Dec;41(12 P 2):e636-50.
Farhan J, Al-Shobaili HA, Zafar U, et al. Interleukin-6: a possible inflammatory link between vitiligo and type 1 diabetes. Br J Biomed Sci. 2014;71(4):151-7.
Kasumagic-Halilovic E, Ovcina-Kurtovic N, Jukic T, et al. Vitiligo and autoimmunity. Med Arch. 2013;67(2):91-3.
Kemp EH, Gavalas NG, Gawkrodger DJ, et al. Autoantibody responses to melanocytes in the depigmenting skin disease vitiligo. Autoimmun Rev. 2007 Jan;6(3):138-42.
Chang HC, Lin MH, Huang YC, et al. The association between vitiligo and diabetes mellitus: A systematic review and meta-analysis. J Am Acad Dermatol. 2019 Dec;81(6):1442-1445.
Raveendra L, Hemavathi RN, Rajgopal S. A Study of Vitiligo in Type 2 Diabetic Patients. Indian J Dermatol. 2017;62(2):168-170.
Choi CW, Eun SH, Choi KH, et al. Increased risk of comorbid rheumatic disorders in vitiligo patients: A nationwide population-based study. J Dermatol. 2017 Aug;44(8):909-913.
Nath SK, Kelly JA, Namjou B, et al. Evidence for a susceptibility gene, SLEV1, on chromosome 17p13 in families with vitiligo-related systemic lupus erythematosus. Am J Hum Genet. 2001 Dec;69(6):1401-6.
Spritz RA, Gowan K, Bennett DC, et al. Novel vitiligo susceptibility loci on chromosomes 7 (AIS2) and 8 (AIS3), confirmation of SLEV1 on chromosome 17, and their roles in an autoimmune diathesis. Am J Hum Genet. 2004 Jan;74(1):188-91.
Li HO, Bailey AMJ, Pastukhova E, et al. Comorbid diagnosis of systemic lupus erythematosus in vitiligo: a systematic review and meta-analysis. Br J Dermatol. 2023 Feb 22;188(3):440-441.
Borimnejad L, Parsa Yekta Z, Nikbakht-Nasrabadi A, et al. Quality of life with vitiligo: comparison of male and female muslim patients in Iran. Gend Med. 2006 Jun;3(2):124-30.
Porter JR, Beuf AH, Lerner AB, et al. The effect of vitiligo on sexual relationships. J Am Acad Dermatol. 1990 Feb;22(2 Pt 1):221-2.
Sukan M, Maner F. The problems in sexual functions of vitiligo and chronic urticaria patients. J Sex Marital Ther. 2007 Jan-Feb;33(1):55-64.
Yucel D, Sener S, Turkmen D, et al. Evaluation of the Dermatological Life Quality Index, sexual dysfunction and other psychiatric diseases in patients diagnosed with vitiligo with and without genital involvement. Clin Exp Dermatol. 2021 Jun;46(4):669-674.
Liang X, Guo F, Cai X, et al. Association between vitiligo and sexual dysfunction: current evidence. Ann Med. 2023 Dec;55(1):946-953.
Morrison B, Burden-Teh E, Batchelor JM, et al. Quality of life in people with vitiligo: a systematic review and meta-analysis. Br J Dermatol. 2017 Dec; 177(6):e338-e339.
Ezzedine K, Eleftheriadou V, Jones H, et al. Psychosocial Effects of Vitiligo: A Systematic Literature Review. Am J Clin Dermatol. 2021 Nov;22(6):757-774.
Yang Y, Zapata L, Rodgers C, et al. Quality of life in patients with vitiligo using the Short Form-36. Br J Dermatol. 2017 Dec;177(6):1764-1766.
Wang G, Qiu D, Yang H, et al. The prevalence and odds of depression in patients with vitiligo: a meta-analysis. J Eur Acad Dermatol Venereol. 2018 Aug;32(8):1343-1351.
Kussainova A, Kassym L, Akhmetova A, et al. Vitiligo and anxiety: A systematic review and meta-analysis. PLoS One. 2020 Nov 10;15(11):e0241445.
Andrade G, Rangu S, Provini L, et al. Childhood vitiligo impacts emotional health of parents: a prospective, cross-sectional study of quality of life for primary caregivers. J Patient Rep Outcomes. 2020 Mar 20;4(1):20.
Ezzedine K, Lim HW, Suzuki T, et al. Vitiligo Global Issue Consensus Conference Panelists. Revised classification/nomenclature of vitiligo and related issues: the Vitiligo Global Issues Consensus Conference. Pigment Cell Melanoma Res. 2012 May;25(3):E1-13.
Plonka PM, Passeron T, Brenner M, et al. What are melanocytes really doing all day long...? Exp Dermatol. 2009 Sep;18(9):799-819.
Hu DN, Simon JD, Sarna T. Role of ocular melanin in ophthalmic physiology and pathology. Photochem Photobiol. 2008 May-Jun;84(3):639-44.
Genedy R, Assal S, Gomaa A, et al. Ocular and auditory abnormalities in patients with vitiligo: a case-control study. Clin Exp Dermatol. 2021 Aug;46(6):1058-1066.
Dertlioğlu SB, Oğuz H, Çiçek D, et al. Prevalence of glaucoma in patients with vitiligo. Cutis. 2016 Apr;97(4):E21-5.
Prabha N, Chhabra N, Shrivastava AK, et al. Ocular Abnormalities in Vitiligo Patients: A Cross-Sectional Study. Indian Dermatol Online J. 2019 Nov 1;10(6):731-734.
Chen CL, Wu CY, Chen YL, Chen CC, Chang YT, Wu CY. Association between vitiligo and risk of retinal detachment: A population-based cohort study in Taiwan. Clin Exp Dermatol. Published online January 25, 2024.
Denat L, Kadekaro AL, Marrot L, et al. Melanocytes as instigators and victims of oxidative stress. J Invest Dermatol. 2014 Jun;134(6):1512-1518.
Wan J, Lin F, Zhang W, et al. Novel approaches to vitiligo treatment via modulation of mTOR and NF-κB pathways in human skin melanocytes. Int J Biol Sci. 2017 Feb 25;13(3):391-400.
Roberts DS, Linthicum FH Jr. Distribution of melanocytes in the human cochlea. Otol Neurotol. 2015 Mar;36(3):e99-100.
Kamogashira T, Fujimoto C, Yamasoba T. Reactive oxygen species, apoptosis, and mitochondrial dysfunction in hearing loss. Biomed Res Int. 2015;2015:617207.
Li CL, Ma SH, Wu CY, Chang PH, Chang YT, Wu CY. Association between sensorineural hearing loss and vitiligo: a nationwide population-based cohort study. J Eur Acad Dermatol Venereol. 2022;36(7):1097-1103.
Ma SH, Ang MD, Chang YT, et al. Association between vitiligo and hearing loss. J Am Acad Dermatol. 2021 Dec;85(6):1465-1472.
Lien KH, Ger TY, Chi CC. Association of vitiligo with high-frequency sensorineural hearing loss: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2022 Mar;36(3):373-379.
in white spots: Vitiligo and associated comorbidities. Front Med (Lausanne). 2023 Feb 23;10:1072837.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Haoyuan Hu, Xiaoning Yan
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
